IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume – Here’s What Happened

Shares of IPSEN (OTCMKTS:IPSEY) saw unusually-strong trading volume on Thursday. Approximately 16,248 shares traded hands during mid-day trading, an increase of 762% from the previous session’s volume of 1,885 shares. The stock last traded at $40.15 and had previously closed at $39.89.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

IPSEN Price Performance

The company’s fifty day simple moving average is $45.18 and its 200 day simple moving average is $46.27.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.